PharmaCyte Biotech Inc. (PMCB) News

PharmaCyte Biotech Inc. (PMCB): $1.83

0.02 (+1.10%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

C

Add PMCB to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#60 of 390

in industry

Filter PMCB News Items

PMCB News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest PMCB News From Around the Web

Below are the latest news stories about PHARMACYTE BIOTECH INC that investors may wish to consider to help them evaluate PMCB as an investment opportunity.

PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024

PharmaCyte Biotech just reported results for the second quarter of 2024.

InvestorPlace Earnings on InvestorPlace | December 18, 2023

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.

LAS VEGAS, November 15, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) ("Femasys"), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions, including a lead late-stage product candidate and innovative therapeutic and diagnostic products. This is the Company’s first investment in externally dev

Yahoo | November 15, 2023

Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech

- $6.85 million upfront investment provides $23 million total cash runway into second half 2025 - - Financing allows for focused commercial team to bring Femasys’ infertility-related products to women in the U.S. - - Additional financing supports the advancement of Femasys’ lead product candidate, FemBloc® for permanent birth control, to initial clinical data readout - ATLANTA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unme

Yahoo | November 15, 2023

PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology

LAS VEGAS, October 31, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") provides an update on its investigation of its Cell-in-a-Box technology and initial next steps in development. Following a comprehensive scientific review of amassed data, the Company is in the process of requesting a meeting with the U.S. Food and Drug Administration (FDA) for guidance on further development of the technology. The meeting is expected to occur during the first quarter of 2024. In

Yahoo | October 31, 2023

PharmaCyte Biotech Announces Final Results of Tender Offer

LAS VEGAS, June 15, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") today announces the final results of its previously announced tender offer to acquire up to 7,750,000 million shares of the Company’s common stock, par value $0.001 per share, at a price of $3.25 per share in cash, less any applicable withholding taxes and without interest. The tender offer expired one minute after 11:59 p.m. on June 9, 2023, and was funded entirely through the Company’s cash on han

Yahoo | June 15, 2023

PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share

LAS VEGAS, May 11, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") today announces a cash tender offer for up to 7,750,000 shares at $3.25 per share, less any applicable withholding taxes and without interest. The Company also announces that it has completed a private placement financing of convertible redeemable preferred stock and warrants from existing investors, raising gross proceeds of approximately $35 million in a private placement financing of convertible r

Yahoo | May 11, 2023

PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan

LAS VEGAS, February 02, 2023--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) ("PharmaCyte" or the "Company"), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-Box® for potential development of cellular therapies for cancer, diabetes and malignant ascites, announced today that its Board of Directors has authorized a second share repurchase program to repurchase up to $10 million of PharmaCyte’s outstanding common stock. This second share repurchase

Yahoo | February 2, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!